These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36150143)

  • 21. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study.
    Sehgal A; Hoda D; Riedell PA; Ghosh N; Hamadani M; Hildebrandt GC; Godwin JE; Reagan PM; Wagner-Johnston N; Essell J; Nath R; Solomon SR; Champion R; Licitra E; Fanning S; Gupta N; Dubowy R; D'Andrea A; Wang L; Ogasawara K; Thorpe J; Gordon LI
    Lancet Oncol; 2022 Aug; 23(8):1066-1077. PubMed ID: 35839786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung Cancer.
    Choudhury NJ; Lai WV; Makhnin A; Heller G; Eng J; Li B; Preeshagul I; Santini FC; Offin M; Ng K; Paik P; Larsen C; Ginsberg MS; Lau Y; Zhang X; Baine MK; Rekhtman N; Rudin CM
    Clin Cancer Res; 2024 Sep; 30(17):3697-3703. PubMed ID: 38940666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Bendamustine monotherapy for Chinese patient treatment with relapsed or refractory B cell non-Hodgkin lymphoma: a phase Ⅱ, prospective, multicenter, single-arm study].
    Gao Y; Yang Y; Cen H; Liu H; Fu JX; Wang SQ; Feng R; Yu D; Zhang XY; Chen ZW; Li YF; Huang HQ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):934-939. PubMed ID: 36709185
    [No Abstract]   [Full Text] [Related]  

  • 25. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
    Ogura M; Imaizumi Y; Uike N; Asou N; Utsunomiya A; Uchida T; Aoki T; Tsukasaki K; Taguchi J; Choi I; Maruyama D; Nosaka K; Chen N; Midorikawa S; Ohtsu T; Tobinai K
    Lancet Haematol; 2016 Mar; 3(3):e107-18. PubMed ID: 26947199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
    Wang M; Fayad L; Wagner-Bartak N; Zhang L; Hagemeister F; Neelapu SS; Samaniego F; McLaughlin P; Fanale M; Younes A; Cabanillas F; Fowler N; Newberry KJ; Sun L; Young KH; Champlin R; Kwak L; Feng L; Badillo M; Bejarano M; Hartig K; Chen W; Chen Y; Byrne C; Bell N; Zeldis J; Romaguera J
    Lancet Oncol; 2012 Jul; 13(7):716-23. PubMed ID: 22677155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study.
    Deng LJ; Zhou KS; Liu LH; Zhang MZ; Li ZM; Ji CY; Xu W; Liu T; Xu B; Wang X; Gao SJ; Zhang HL; Hu Y; Li Y; Cheng Y; Yang HY; Cao JN; Zhu ZM; Hu JD; Zhang W; Jing HM; Ding KY; Zhang XY; Zhao RB; Zhang B; Tian YM; Song YP; Song YQ; Zhu J
    Blood Adv; 2023 Aug; 7(16):4349-4357. PubMed ID: 37078706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma.
    Fowler NH; Samaniego F; Jurczak W; Ghosh N; Derenzini E; Reeves JA; Knopińska-Posłuszny W; Cheah CY; Phillips T; Lech-Maranda E; Cheson BD; Caimi PF; Grosicki S; Leslie LA; Chavez JC; Fonseca G; Babu S; Hodson DJ; Shao SH; Burke JM; Sharman JP; Law JY; Pagel JM; Miskin HP; Sportelli P; O'Connor OA; Weiss MS; Zinzani PL
    J Clin Oncol; 2021 May; 39(15):1609-1618. PubMed ID: 33683917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
    Berdeja JG; Madduri D; Usmani SZ; Jakubowiak A; Agha M; Cohen AD; Stewart AK; Hari P; Htut M; Lesokhin A; Deol A; Munshi NC; O'Donnell E; Avigan D; Singh I; Zudaire E; Yeh TM; Allred AJ; Olyslager Y; Banerjee A; Jackson CC; Goldberg JD; Schecter JM; Deraedt W; Zhuang SH; Infante J; Geng D; Wu X; Carrasco-Alfonso MJ; Akram M; Hossain F; Rizvi S; Fan F; Lin Y; Martin T; Jagannath S
    Lancet; 2021 Jul; 398(10297):314-324. PubMed ID: 34175021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
    Brown JR; Hamadani M; Hayslip J; Janssens A; Wagner-Johnston N; Ottmann O; Arnason J; Tilly H; Millenson M; Offner F; Gabrail NY; Ganguly S; Ailawadhi S; Kasar S; Kater AP; Doorduijn JK; Gao L; Lager JJ; Wu B; Egile C; Kersten MJ
    Lancet Haematol; 2018 Apr; 5(4):e170-e180. PubMed ID: 29550382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bendamustine in the treatment of patients with indolent non-Hodgkin lymphoma refractory or relapse to rituximab treatment: An open-label, single-agent, multicenter study in China.
    Gao Y; Liu Y; Wang Y; Zhang Q; Wu D; Ye X; Wu J; Xu W; Zhou J; Yang Y; Cen H; Zhang F; Xiang Y; Tang X; Ding K; Lin J; Ma L; Wang S; Yu H; Zhao Y; Song B; Lv F; Huang H
    Cancer; 2023 Feb; 129(4):551-559. PubMed ID: 36541221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.
    Abramson JS; Palomba ML; Gordon LI; Lunning M; Wang M; Arnason J; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Dehner C; Kim Y; Ogasawara K; Kostic A; Siddiqi T
    Blood; 2024 Feb; 143(5):404-416. PubMed ID: 37890149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma.
    Chen R; Frankel P; Popplewell L; Siddiqi T; Ruel N; Rotter A; Thomas SH; Mott M; Nathwani N; Htut M; Nademanee A; Forman SJ; Kirschbaum M
    Haematologica; 2015 Mar; 100(3):357-62. PubMed ID: 25596263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    Morschhauser F; Fitoussi O; Haioun C; Thieblemont C; Quach H; Delarue R; Glaisner S; Gabarre J; Bosly A; Lister J; Li J; Coiffier B
    Eur J Cancer; 2013 Sep; 49(13):2869-76. PubMed ID: 23731832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
    Ailawadhi S; Chen Z; Huang B; Paulus A; Collins MC; Fu LT; Li M; Ahmad M; Men L; Wang H; Davids MS; Liang E; Mekala DJ; He Z; Lasica M; Yannakou CK; Parrondo R; Glass L; Yang D; Chanan-Khan A; Zhai Y
    Clin Cancer Res; 2023 Jul; 29(13):2385-2393. PubMed ID: 37074726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
    Satake A; Konishi A; Azuma Y; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Ito T; Ishii K; Nomura S
    Eur J Haematol; 2020 Dec; 105(6):704-711. PubMed ID: 32564395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
    Kalakonda N; Maerevoet M; Cavallo F; Follows G; Goy A; Vermaat JSP; Casasnovas O; Hamad N; Zijlstra JM; Bakhshi S; Bouabdallah R; Choquet S; Gurion R; Hill B; Jaeger U; Sancho JM; Schuster M; Thieblemont C; De la Cruz F; Egyed M; Mishra S; Offner F; Vassilakopoulos TP; Warzocha K; McCarthy D; Ma X; Corona K; Saint-Martin JR; Chang H; Landesman Y; Joshi A; Wang H; Shah J; Shacham S; Kauffman M; Van Den Neste E; Canales MA
    Lancet Haematol; 2020 Jul; 7(7):e511-e522. PubMed ID: 32589977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial.
    Melani C; Dowdell K; Pittaluga S; Dunleavy K; Roschewski M; Song JY; Calattini S; Kawada JI; Price DA; Chattopadhyay PK; Roederer M; Lucas AN; Steinberg SM; Jaffe ES; Cohen JI; Wilson WH
    Lancet Haematol; 2023 May; 10(5):e346-e358. PubMed ID: 37011643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.